Dr. Prescott reviews advances in therapies for Alzheimer’s disease, Parkinson’s disease, autism, schizophrenia, methamphetamine addiction, and cognition in Down syndrome as well as a possible relationship between isotretinoin and depression.
You are here
P&T® Journal contents for November 2004
Demographics, Practices, and Prescribing Characteristics of Physicians Who Are Early Adopters of New Drugs
The factors that influence physicians to prescribe novel first-in-class drugs and later follow-on (established) drugs are explored.
Part 1: The Evolution
The authors discuss the origins of drug formularies and the changing role of P&T committees.
The authors review a coagulation factor therapy for patients at risk for bleeding.
Caregivers of pediatric patients with AOMT were more satisfied with ciprofloxacin/dexamethasone than ofloxacin in healing otorrhea.
The FDA has issued new labeling changes for efavirenz, rituximab, levothyroxine, zoledronic acid, infliximab, and some of the second-generation antidepressants.